ALTITUDE trial and dual RAS blockade: the alluring but soft science of the surrogate end point.

@article{Messerli2013ALTITUDETA,
  title={ALTITUDE trial and dual RAS blockade: the alluring but soft science of the surrogate end point.},
  author={Franz H. Messerli and Sripal Bangalore},
  journal={The American journal of medicine},
  year={2013},
  volume={126 3},
  pages={
          e1-3
        }
}
i t p c p On December 20, 2011, the large, landmark Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) was terminated on the basis of the recomendations of the Data and Safety Monitoring Board. he ALTITUDE was designed to evaluate the effects of liskiren versus placebo on top of an angiotensin receptor locker or an angiotensin-converting enzyme inhibitor in ore than 8000 patients with type II diabetes and renal mpairment. An increased incidence of hypotension… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 12 REFERENCES

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2009
VIEW 2 EXCERPTS

Similar Papers

Loading similar papers…